S&R Associates Represented Glenmark Pharmaceuticals In ₹7.98 Billion Equity Sale Of Glenmark Life Sciences
S&R Associates represented Glenmark Pharmaceuticals Limited, a listed pharmaceutical company, and an affiliate in the INR 7.98
S&R Associates Represented Glenmark Pharmaceuticals In ₹7.98 Billion Equity Sale Of Glenmark Life Sciences
S&R Associates represented Glenmark Pharmaceuticals Limited, a listed pharmaceutical company, and an affiliate in the INR 7.98 billion sale of 7.85 per cent of the equity shares of Glenmark Life Sciences Limited (GLS), a listed active pharmaceutical ingredients manufacturer, pursuant to an offer for sale on the BSE and the NSE.
GLS is a top producer and creator of unique, valuable, and non-commoditized active medicinal components. The 146 compounds in the company's portfolio address chronic treatment areas such as diabetes, pain management, central nervous system disorders, and cardiovascular disease.
The S&R team was led by Partners Rajat Sethi and Pratichi Mishra, and included Associates Samyak Jain and Oshika Nayak.